TRXADE HEALTH INC (MEDS) Stock Analyst Earnings Estimates
NASDAQ:MEDS - Nasdaq - US89846A4058 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|
| Revenue YoY % growth | 9.89M -42.23% | 11.45M 15.77% | 8.272M -27.75% | 9.486M 14.67% | |
| EBITDA YoY % growth | -4.05M -128.81% | -2.74M 32.35% | -6.429M -134.64% | -663K 89.69% | |
| EBIT YoY % growth | -4.06M -128.09% | -2.75M 32.27% | -7.263M -164.12% | -887.4K 87.78% | |
| Operating Margin | -41.05% | -24.02% | -87.80% | -9.35% | |
| EPS YoY % growth | -1.91 -730.43% | -4.80 -151.31% | N/A 77.69% | -0.46 57.14% |
All data in USD
| Q3 / 24 | Q4 / 24 | |
|---|---|---|
| EPS Q2Q % growth | -0.15 | 0.00 100.00% |
| Revenue Q2Q % growth | 2.525M 22.69% | 2.591M 10.14% |
| EBITDA Q2Q % growth | -137.7K 73.04% | -40.8K 99.24% |
| EBIT Q2Q % growth | -193.8K 77.07% | -96.9K 98.44% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 94.72% | -0.15 | % | |
| Q1 2024 Q2Q % growth | 85.43% | -0.15 | % | |
| Q4 2023 Q2Q % growth | -2.00% | -0.15 | % | |
| Q3 2023 Q2Q % growth | 83.00% | -0.15 | % | |
| Q2 2023 Q2Q % growth | -2.90 -48.72% | -0.77 | -2.14 | -279.08% |
| Q1 2023 Q2Q % growth | -1.05 41.67% | -0.46 | -0.59 | -128.76% |
| Q4 2022 Q2Q % growth | -0.15 90.00% | -0.99 | 0.84 | 84.92% |
| Q3 2022 Q2Q % growth | -0.90 -462.50% | -1.84 | 0.94 | 50.98% |
| Q2 2022 Q2Q % growth | -1.95 -1,047.06% | -1.53 | -0.42 | -27.45% |
| Q1 2022 Q2Q % growth | -1.80 -2,150.00% | -1.73 | -0.07 | -3.81% |
| Q4 2021 Q2Q % growth | -1.50 -650.00% | -2.30 | 0.79 | 34.64% |
| Q3 2021 Q2Q % growth | -0.16 -900.00% | -0.13 | -0.03 | -20.66% |
| Q2 2021 Q2Q % growth | -0.17 -142.86% | -0.09 | -0.08 | -92.30% |
| Q1 2021 Q2Q % growth | -0.08 -500.00% | -0.05 | -0.03 | -68.06% |
| Q4 2020 Q2Q % growth | -0.20 | 0.01 | -0.21 | -2,060.78% |
| Q3 2020 Q2Q % growth | 0.02 | 0.03 | -0.01 | -34.64% |
| Q2 2020 Q2Q % growth | -0.07 | 0.01 | -0.08 | -786.27% |
| Q1 2020 Q2Q % growth | 0.02 | 0.01 | 0.01 | 96.08% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 18.7K -99.17% | 2.28M | -2.261M | -99.18% |
| Q1 2024 Q2Q % growth | -100.00% | 2.091M | -2.091M | -100.00% |
| Q4 2023 Q2Q % growth | 2.352M -7.02% | 2.392M | -39.57K | -1.65% |
| Q3 2023 Q2Q % growth | 2.058M -14.25% | 2.326M | -267.97K | -11.52% |
| Q2 2023 Q2Q % growth | 2.251M -31.37% | 2.101M | 150.08K | 7.14% |
| Q1 2023 Q2Q % growth | 2.248M -30.63% | 2.716M | -468.25K | -17.24% |
| Q4 2022 Q2Q % growth | 2.53M 5.86% | 2.563M | -33K | -1.29% |
| Q3 2022 Q2Q % growth | 2.4M -5.88% | 3.367M | -967K | -28.72% |
| Q2 2022 Q2Q % growth | 3.28M 72.63% | 2.989M | 291K | 9.74% |
| Q1 2022 Q2Q % growth | 3.24M 6.23% | 2.252M | 988K | 43.87% |
| Q4 2021 Q2Q % growth | 2.39M 20.10% | 2.122M | 268K | 12.63% |
| Q3 2021 Q2Q % growth | 2.55M -59.72% | 2.029M | 521K | 25.68% |
| Q2 2021 Q2Q % growth | 1.9M -71.17% | 2.321M | -421K | -18.14% |
| Q1 2021 Q2Q % growth | 3.05M 38.64% | 2.235M | 815K | 36.47% |
| Q4 2020 Q2Q % growth | 1.99M 17.06% | 3.493M | -1.503M | -43.03% |
| Q3 2020 Q2Q % growth | 6.33M 174.03% | 3.07M | 3.26M | 106.19% |
| Q2 2020 Q2Q % growth | 6.59M 243.23% | 2.196M | 4.394M | 200.09% |
| Q1 2020 Q2Q % growth | 2.2M 45.70% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | 0% | 0% | 0% | 0% |